Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $1.1 billion.

  • Kymera Therapeutics' Liabilities and Shareholders Equity rose 649.39% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 billion, marking a year-over-year increase of 2495.06%. This contributed to the annual value of $978.0 million for FY2024, which is 6986.88% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Liabilities and Shareholders Equity stood at $1.1 billion, which was up 649.39% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Liabilities and Shareholders Equity ranged from a high of $1.1 billion in Q2 2025 and a low of $434.4 million during Q2 2021
  • In the last 5 years, Kymera Therapeutics' Liabilities and Shareholders Equity had a median value of $613.9 million in 2023 and averaged $718.8 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 1348.44% in 2023, then surged by 8734.31% in 2024.
  • Quarter analysis of 5 years shows Kymera Therapeutics' Liabilities and Shareholders Equity stood at $605.9 million in 2021, then fell by 0.46% to $603.1 million in 2022, then decreased by 4.54% to $575.8 million in 2023, then skyrocketed by 69.87% to $978.0 million in 2024, then increased by 12.68% to $1.1 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.1 billion in Q3 2025, compared to $1.1 billion in Q2 2025 and $918.3 million in Q1 2025.